Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Equity Ratio (2016 - 2025)

Lexaria Bioscience's Equity Ratio history spans 11 years, with the latest figure at 0.75 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 22.06% year-over-year to 0.75; the TTM value through Nov 2025 reached 0.75, down 22.06%, while the annual FY2025 figure was 0.72, 17.09% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.75 at Lexaria Bioscience, up from 0.72 in the prior quarter.
  • Across five years, Equity Ratio topped out at 153.32 in Q2 2024 and bottomed at 0.72 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.98 (2022), against an average of 17.08.
  • The largest annual shift saw Equity Ratio surged 7834.43% in 2023 before it tumbled 99.46% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.98 in 2021, then rose by 3.27% to 1.01 in 2022, then skyrocketed by 4287.11% to 44.24 in 2023, then tumbled by 97.83% to 0.96 in 2024, then fell by 22.06% to 0.75 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Equity Ratio are 0.75 (Q4 2025), 0.72 (Q3 2025), and 0.82 (Q2 2025).